SE436875B - Pyrimidinderivat - Google Patents

Pyrimidinderivat

Info

Publication number: SE436875B
Authority: SE; Sweden
Prior art keywords: methyl; hydroxymethyl; hydroxy; isopropylidenyl; piperazinyl
Prior art date: 1977-07-12

Application number

SE7807721A

Other languages

English (en)

Swedish (sv)

Other versions

SE7807721L (sv

Inventor

A Beguin

Original Assignee

Scras

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-07-12

Filing date

1978-07-11

Publication date

1985-01-28

1978-07-11 Application filed by Scras filed Critical Scras

1979-01-13 Publication of SE7807721L publication Critical patent/SE7807721L/xx

1985-01-28 Publication of SE436875B publication Critical patent/SE436875B/sv

Links

CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 claims description 7
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims 1
150000003230 pyrimidines Chemical class 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
WUGTXQVNSRFDNV-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine Chemical compound CC1=CC(Cl)=CC(Cl)=N1 WUGTXQVNSRFDNV-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
235000008160 pyridoxine Nutrition 0.000 description 2
239000011677 pyridoxine Substances 0.000 description 2
125000002181 pyridoxine group Chemical group 0.000 description 2
238000003756 stirring Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
229940011671 vitamin b6 Drugs 0.000 description 2
-1 2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridylmethyl Chemical group 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
201000005577 familial hyperlipidemia Diseases 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

SE7807721A 1977-07-12 1978-07-11 Pyrimidinderivat SE436875B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB2928177		1977-07-12

Publications (2)

Publication Number	Publication Date
SE7807721L SE7807721L (sv)	1979-01-13
SE436875B true SE436875B (sv)	1985-01-28

Family

ID=10289056

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7807721A SE436875B (sv)	1977-07-12	1978-07-11	Pyrimidinderivat

Country Status (28)

Country	Link
US (1)	US4174395A (pt)
JP (1)	JPS5452088A (pt)
AR (1)	AR218072A1 (pt)
AT (1)	AT358198B (pt)
AU (1)	AU517046B2 (pt)
BE (1)	BE868539A (pt)
CA (1)	CA1097645A (pt)
CH (1)	CH632267A5 (pt)
DE (1)	DE2830670C2 (pt)
DK (1)	DK148685C (pt)
EG (1)	EG13550A (pt)
ES (1)	ES471608A1 (pt)
FI (1)	FI63026C (pt)
FR (2)	FR2397413A1 (pt)
HK (1)	HK18783A (pt)
IE (1)	IE47027B1 (pt)
IN (1)	IN148661B (pt)
LU (1)	LU79916A1 (pt)
MX (1)	MX5103E (pt)
MY (1)	MY8500031A (pt)
NL (1)	NL170855C (pt)
NO (1)	NO149846C (pt)
NZ (1)	NZ187655A (pt)
OA (1)	OA06120A (pt)
PT (1)	PT68268A (pt)
SE (1)	SE436875B (pt)
SG (1)	SG60982G (pt)
ZA (1)	ZA783521B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT387221B (de) *	1980-09-08	1988-12-27	Bristol Myers Co	Verfahren zur herstellung des neuen
US6854146B2 (en)	2000-06-12	2005-02-15	Milliken & Company	Method for producing digitally designed carpet

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2459367A (en) *	1947-11-12	1949-01-18	American Cyanamid Co	1,4-di (heterocyclic substituted) piperazines
US2606906A (en) *	1948-10-14	1952-08-12	American Cyanamid Co	1-(2-pyridyl) piperazine and process of preparing same
US2748125A (en) *	1954-04-26	1956-05-29	American Cyanamid Co	1-substituted-4-sulfamylpiperazine and method of preparing the same
GB1433222A (pt) *	1973-03-28	1976-04-22	Prod Ch8Mi Soc Et

1978
- 1978-06-20 ZA ZA00783521A patent/ZA783521B/xx unknown
- 1978-06-21 FI FI781982A patent/FI63026C/fi not_active IP Right Cessation
- 1978-06-21 IN IN457/DEL/78A patent/IN148661B/en unknown
- 1978-06-22 NZ NZ187655A patent/NZ187655A/xx unknown
- 1978-06-28 BE BE188906A patent/BE868539A/xx not_active IP Right Cessation
- 1978-06-29 AT AT474578A patent/AT358198B/de not_active IP Right Cessation
- 1978-07-03 US US05/921,335 patent/US4174395A/en not_active Expired - Lifetime
- 1978-07-04 LU LU79916A patent/LU79916A1/xx unknown
- 1978-07-04 NL NLAANVRAGE7807228,A patent/NL170855C/xx not_active IP Right Cessation
- 1978-07-07 CH CH741778A patent/CH632267A5/fr not_active IP Right Cessation
- 1978-07-10 IE IE1383/78A patent/IE47027B1/en unknown
- 1978-07-10 PT PT68268A patent/PT68268A/pt unknown
- 1978-07-10 CA CA307,056A patent/CA1097645A/en not_active Expired
- 1978-07-11 AR AR272915A patent/AR218072A1/es active
- 1978-07-11 EG EG435/78A patent/EG13550A/xx active
- 1978-07-11 MX MX787221U patent/MX5103E/es unknown
- 1978-07-11 ES ES471608A patent/ES471608A1/es not_active Expired
- 1978-07-11 DK DK310678A patent/DK148685C/da active
- 1978-07-11 SE SE7807721A patent/SE436875B/sv not_active IP Right Cessation
- 1978-07-11 NO NO782408A patent/NO149846C/no unknown
- 1978-07-11 JP JP8362078A patent/JPS5452088A/ja active Granted
- 1978-07-11 AU AU37934/78A patent/AU517046B2/en not_active Expired
- 1978-07-12 FR FR7820755A patent/FR2397413A1/fr active Granted
- 1978-07-12 DE DE2830670A patent/DE2830670C2/de not_active Expired
- 1978-07-12 FR FR7820756A patent/FR2400362A1/fr active Granted
- 1978-09-25 OA OA56615A patent/OA06120A/xx unknown
1982
- 1982-12-03 SG SG609/82A patent/SG60982G/en unknown
1983
- 1983-06-02 HK HK187/83A patent/HK18783A/xx unknown
1985
- 1985-12-30 MY MY31/85A patent/MY8500031A/xx unknown

Also Published As

Publication number	Publication date
IE781383L (en)	1979-01-12
AU3793478A (en)	1980-01-17
IE47027B1 (en)	1983-11-30
DK310678A (da)	1979-01-13
SE7807721L (sv)	1979-01-13
SG60982G (en)	1983-09-02
JPS5452088A (en)	1979-04-24
ZA783521B (en)	1979-06-27
NZ187655A (en)	1980-10-24
PT68268A (en)	1978-08-01
OA06120A (fr)	1981-06-30
FR2400362B1 (pt)	1980-06-06
IN148661B (pt)	1981-05-02
FI63026C (fi)	1983-04-11
NO149846B (no)	1984-03-26
NL7807228A (nl)	1979-01-16
DK148685B (da)	1985-09-02
AU517046B2 (en)	1981-07-02
FI63026B (fi)	1982-12-31
FI781982A7 (fi)	1979-01-13
MX5103E (es)	1983-03-16
HK18783A (en)	1983-06-10
EG13550A (en)	1982-03-31
AR218072A1 (es)	1980-05-15
DE2830670A1 (de)	1979-01-18
AT358198B (de)	1980-08-25
MY8500031A (en)	1985-12-31
NL170855B (nl)	1982-08-02
BE868539A (fr)	1978-10-16
FR2400362A1 (fr)	1979-03-16
DE2830670C2 (de)	1983-01-20
NO782408L (no)	1979-01-15
FR2397413B1 (pt)	1980-07-18
NO149846C (no)	1984-07-04
DK148685C (da)	1986-02-17
US4174395A (en)	1979-11-13
FR2397413A1 (fr)	1979-02-09
CH632267A5 (fr)	1982-09-30
LU79916A1 (pt)	1978-12-07
NL170855C (nl)	1983-01-03
ATA474578A (de)	1980-01-15
CA1097645A (en)	1981-03-17
JPS5725554B2 (pt)	1982-05-29
ES471608A1 (es)	1979-01-16

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7807721-1

Effective date: 19920210

Format of ref document f/p: F

Publication	Publication Date	Title
AU692439B2 (en)	1998-06-11	Heterocyclic compounds as platelet aggregation inhibitors
DE60004564T2 (de)	2004-06-24	Neue piperidin und piperazin-derivate als p2x7-rezeptor antagonisten
DE10148618B4 (de)	2007-05-03	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DD246995A5 (de)	1987-06-24	Verfahren zur herstellung von neuen schwefelhaltigen 5-substituierten benzimidazol-derivaten
HU179745B (en)	1982-12-28	Process for preparing new phthalazine derivatives and pharmaceutical compositions containing these compounds
CZ9797A3 (en)	1997-08-13	Triazole derivative, process of its preparation and pharmaceutical composition containing thereof
KR900003490B1 (ko)	1990-05-21	쯔비터이온성 비사이클릭 화합물 및 이의 염, 용매화물, 수화물 및 에스테르, 이의 제조방법 및 이를 함유하는 약제학적 조성물
NZ234564A (en)	1991-04-26	1-substituted benzimidazoles and pharmaceutical compositions
KR19990044275A (ko)	1999-06-25	신규 2,3-디옥소-1,2,3,4-테트라히드로-퀴녹살리닐 유도체
DK157932B (da)	1990-03-05	1,3-dihydro-6-methyl-furo-(3,4-c)-pyridin-derivater og farmaceutiske acceptable salte deraf samt farmaceutisk praeparat indeholdende disse
TW580498B (en)	2004-03-21	A novel amide compound and a pharmaceutical composition containing the same
US4179563A (en)	1979-12-18	3-Aryloxy-substituted-aminopyridines and methods for their production
DD213920A5 (de)	1984-09-26	Verfahren zur herstellung von dihydropyridinen
CA3042107C (en)	2023-03-07	Ire-1.alpha. inhibitors
CS241549B2 (en)	1986-03-13	Method of 1,4-dihydropyridines production
US3169966A (en)	1965-02-16	Aminopyrazoles
AU651629B2 (en)	1994-07-28	Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
CS255897B2 (en)	1988-03-15	Process for preparing 1,2,4-triazolocarbamates
EP2760839B1 (en)	2015-11-25	Pyridinedione carboxamide inhibitors of endothelial lipase
US4933354A (en)	1990-06-12	2-pyrrolidone-5-carboxylic acid compounds useful for the treatment of mental disorders
SE436875B (sv)	1985-01-28	Pyrimidinderivat
RU2140919C1 (ru)	1999-11-10	Производные 8-трифторметилхинолинкарбоновой кислоты, фармацевтическая композиция и способ ингибирования вируса иммунодефицита
JPH03106875A (ja)	1991-05-07	１―（３―ピリジルメチル）フタラジン誘導体
CS226020B2 (en)	1984-03-19	Method of preparing pyridine and pyrimidine derivatives
EP0430693B1 (en)	1995-05-31	Pyrimidinedione derivative compounds, method for preparing same, and antiarrhythmic agents containing same